Low Vaccination Concerns Highlight Need for Fall and Winter 2023 Vaccination Campaigns
September 28th 2023Cases of COVID-19, RSV, and influenza are expected to rise this fall and winter season; yet, the number of people who plan on getting the vaccines for each of the infections remains low, according to the NFID announcement today.
Eagle Pharmaceuticals Announces Phase 2 Study for Anti-Toxin Drug Candidate for SCABP
August 21st 2023Eagle Pharmaceuticals randomized its first patient in the Phase 2 study of CAL02, a safe and promising anti-toxin drug that treats severe community-acquired bacterial pneumonia without contributing to antibiotic resistance.
FDA Approves RSV Drug for Children Up to 24 Months
July 17th 2023AstraZeneca's new drug, a monoclonal antibody, was given FDA approval after the Antimicrobial Drugs Advisory Committee (AMDAC) to the FDA voted in June to recommend the approval of nirsevimab (Beyfortus) for the prevention of respiratory syncytial virus (RSV) disease in infants.